从化疗到靶向治疗：通过遗传学和非遗传学见解解析急性髓系白血病的耐药性

From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights.

作者信息

Cao Shuting, Wang Qiuxia, Zhu Ganqian

机构信息

School of Biomedical Sciences, Hunan University, Changsha 410082, China.

出版信息

Int J Mol Sci. 2025 Apr 24;26(9):4005. doi: 10.3390/ijms26094005.

DOI:10.3390/ijms26094005

PMID:40362245

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12071668/

Abstract

Acute myeloid leukemia (AML) is a devastating disease characterized by extensive inter-patient and intra-patient heterogeneity. Despite the introduction of intensive chemotherapy in the 1970s as the standard treatment, the development of mechanism-based targeted therapies since 2017 has been broadening the therapeutic landscape. However, both chemotherapy and targeted therapies continue to face the challenges of primary and secondary resistance. This review summarizes the mechanisms underlying resistance to chemotherapy and targeted therapies in AML and discusses the opportunities and challenges brought by the transition from chemotherapy to precision medicine.

摘要

急性髓系白血病（AML）是一种具有严重破坏性的疾病，其特点是患者之间和患者体内存在广泛的异质性。尽管在20世纪70年代引入了强化化疗作为标准治疗方法，但自2017年以来基于机制的靶向治疗的发展一直在拓宽治疗格局。然而，化疗和靶向治疗都继续面临原发性和继发性耐药的挑战。本综述总结了AML中对化疗和靶向治疗耐药的潜在机制，并讨论了从化疗向精准医学转变所带来的机遇和挑战。